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Introduction: The aim of this study was to investigate the effects of levosimendan on rodent septic shock induced
by cecal ligation and puncture (CLP).
Methods: Three hours after peritonitis-induced sepsis, male Wistar rats were randomly assigned to receive an
intravenous infusion of levosimendan (1.2 μg/kg/min for 10 min and then 0.3 μg/kg/min for 6 h) or an equivalent
volume of saline and vehicle (5% dextrose) solution.
Results: The levosimendan-treated CLP animals had significantly higher arterial pressure and lower biochemical indices
of liver and kidney dysfunction compared to the CLP animals (P < 0.05). Plasma interleukin-1β, nitric oxide and organ
superoxide levels in the levosimendan-treated CLP group were less than those in CLP rats treated with vehicle
(P < 0.05). In addition, the inducible nitric oxide synthase (iNOS) in lung and caspase-3 expressions in spleen
were significantly lower in the levosimendan-treated CLP group (P < 0.05). The administration of CLP rats with
levosimendan was associated with significantly higher survival (61.9% vs. 40% at 18 h after CLP, P < 0.05). At postmortem
examination, the histological changes and neutrophil filtration index in liver and lung were significantly attenuated in
the levosimendan-treated CLP group (vs. CLP group, P < 0.05).
Conclusions: In this clinically relevant model of septic shock induced by fecal peritonitis, the administration of
levosimendan had beneficial effects on haemodynamic variables, liver and kidney dysfunction, and metabolic acidosis.
(1) Lower levels of interleukin-1β, nitric oxide and superoxide, (2) attenuation of iNOS and caspase-3 expressions, and
(3) decreases of neutrophil infiltration by levosimendan in peritonitis-induced sepsis animals suggest that anti-inflammation
and anti-apoptosis effects of levosimendan contribute to prolonged survival.Introduction
Despite better understanding of sepsis pathophysiology
and improved advanced care in the past decade, the inci-
dence and mortality of sepsis has substantially increased.
In the presence of septic shock and associated multiple
organ failure, mortality may approach 30 to 40% [1-3].
Considering that severe sepsis may potentially reduce re-
gional tissue perfusion, the use of vasodilators to open
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unless otherwise stated.in sepsis is reasonable [4,5]. Our previous study has also
demonstrated that terbutaline, a β2-adrenoceptor agonist
inducing peripheral vasodilation via the cyclic adenosine
monophosphate pathway, reduces organ dysfunction and
mortality in rats with severe sepsis [6].
The calcium sensitizer, Levosimendan (LS) enhances
cardiac contractility independent from the adrenergic
system by means of binding to the troponin C within
cardiomyocytes [7]. In addition, LS causes venous, arter-
ial and coronary vasodilation, probably by opening ATP-
sensitive potassium channels (KATP) in smooth muscle
[8]. Experimental data show that LS improves cardiac
performance and organ blood flow during experimental
and human septic shock [9-12]. More importantly, both
clinical and experimental studies manifest that LS hasis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to its cardiovascular effects [13-15]. In a rat model of severe
sepsis induced by cecal ligation and incision, inhaled LS
has been found to reduce the releases of plasma IL-1β and
IL-6 and expression of splenic caspase-3 [16].
Therefore, we examined the hypothesis that short-term
infusion of LS administered after the establishment of
peritonitis-induced sepsis would attenuate succeeding
organ injury and increase survival in a more clinically
relevant model of septic shock. In addition, we investigated
the effect of LS on haemodynamics, pro-inflammatory
cytokines, free radicals and caspase-3 expression, which
may be associated with the organ dysfunction induced by
sepsis.Materials and methods
All work in this study was approved by the Committee on
the Ethics of Animal Experiments of National Defence
Medical Centre (permit number IACUC-10-151), and the
care and handling of the animals were in adherence to the
National Institutes of Health Guidelines for ethical animal
treatment. Male adult Wistar rats (280 to 350 g body
weight), purchased from the National Laboratory Animal
Centre of Taiwan, were kept on a 12-h light/dark cycle at
a controlled temperature (21 ± 2°C) with free access to
food and tap water.Surgical procedures
Rats were anaesthetised using intraperitoneal pentobar-
bital (40 to 50 mg/kg) and inhalation of isoflurane (0.5 to
1.0%). Unconscious rats were tested for sufficient depth of
anaesthesia by pinching their toes. Polyurethane catheters
for blood pressure measurement and drug administration
were inserted into left carotid artery and right jugular vein,
respectively. Subsequently, the catheters were positioned
posteriorly, fixed to the back of the neck. The cannulated
animals were allowed to recover to their normal condition
overnight with standardised pellet food and tap water
ad libitum.
After measurement of baseline haemodynamic analysis
and collection of an arterial blood sample, the intraperi-
toneal sepsis was then induced by cecal ligation and
puncture (CLP) using methods described previously [17].
Briefly, a 2-cm-long midline laparotomy was performed
under sufficient anaesthesia. The exposed cecum was li-
gated with a 3-0 silk ligature just distal to the ileocecal
valve, punctured twice with an 18-gauge needle. In the
sham of control (SOP) group, cecal exposure was per-
formed without any other manipulation. The cecum was
then replaced into the abdomen and the abdominal inci-
sion was closed. All animals immediately received 0.9%
NaCl solution (10 mL/kg subcutaneously) for intraopera-
tive fluid loss.All rats used in the study were kept in the small in-
house animal facility of our institute to enable optimal
monitoring: the overall health status was checked every
4 to 6 h for signs of distress. A subset of rats did not
survive 18 h after induction of sepsis, and specifically,
rats were euthanised only at the end of each experiment
(at 18 h after CLP or sham surgery) or upon signs of
imminent death (that is, unresponsive to external stim-
uli, inability to maintain an upright position, tremor and
prolonged/deep hypothermia and/or agonal breathing)
by using an overdose of pentobarbital (100 mg/Kg, given
intravenously (i.v.)). Then, some tissue specimens of liver
and lung were immediately exercised to analyze super-
oxide levels, western blotting and histological changes.
In addition, the survival rate at 18 h in each group was
analysed.
Experimental protocol
Animals were divided into sham and CLP groups, and
then i.v. infused with LS (1.2 μg/kg/minute for 10 minutes
followed by 0.3 μg/kg/minute for 6 h), or the same volume
of 9% saline and 5% dextrose solution in each group at 3 h
after the sham and the CLP operation. LS (Orion Corpor-
ation, Espoo, Finland) was dissolved in 5% dextrose solu-
tion and its concentration was 0.01 mg/mL. Each arterial
blood sample (0.8 mL) was collected at baseline (that is,
time 0) and at specified times (that is, at 3, 9, and 18 h
after CLP or sham surgery). An equal volume of sterile
saline was used to immediately replace each volume of
withdrawn blood.
Measurement of haemodynamic parameters
The arterial catheter was connected to a pressure trans-
ducer (P23ID, Statham, Oxnard, CA, USA) for the meas-
urement of phasic blood pressure and heart rate, which
were displayed on a polygraph recorder (MacLab/4e, AD
Instruments Pty Ltd., Castle Hill, Australia). The changes
in haemodynamics were recorded at 0, 3, 9 and 18 h after
CLP or sham surgery. After recording haemodynamic pa-
rameters at each time point, animals were intravenously
given a norepinephrine (NE) bolus (1 μg/kg) to examine
their vasopressor responses [18-20]. In order to normalise
all results of vasopressor responses to their baseline values
in all groups, we calculated the values at time 0 of each
group as 100%.
Quantification of organ function and injury
Some arterial blood (180 μL) was used to analyse the
levels of pH, carbon dioxide tension (PaCO2), bicarbon-
ate (HCO3
-), base excess and potassium concentration by
an arterial blood gas analyzer (AVL OPTI Critical Care
Analyzer, AVL Scientific Corp., Roswell, GA, USA). Blood
glucose was analysed by a One-Touch II blood glucose
monitoring system (Lifescan Inc., Milpitas, CA, USA) with
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immediately centrifuged at 7,500 g for 2 minutes to ob-
tain the plasma. Plasma (80 μL) was used to analyse
the biochemical parameters of liver and kidney func-
tion. Liver function was assessed by measuring plasma
levels of aspartate aminotransferase (AST) and alanine
aminotransferase (ALT), and renal function was assessed
by plasma levels of blood urea nitrogen (BUN) and cre-
atinine. In addition, plasma lactate dehydrogenase (LDH)
was measured to evaluate the extent of organ injury. All of
these biochemical parameters were analysed by Fuji DRI-
CHEM 3030 (Fuji Photo Film Co., Ltd., Tokyo, Japan).Measurement of plasma nitric oxide concentrations
The plasma samples (30 μL) were used to measure plasma
nitric oxide (NO) concentration, which in the study is
actually depicted as the total nitrite and nitrate con-
centration in plasma. The nitrite/nitrate concentrations
in all samples were measured using chemiluminescence,
as previously described [21,22]. The amounts of nitrate in
the plasma were measured by adding a reducing gent
(0.8% VCl3 in 1 N HCl) to the purge vessel to convert ni-
trate to NO · , which was stripped from the plasma by
using helium purge gas. The NO · was then drawn into a
nitric oxide analyzer (Sievers 280 NOA; Sievers Inc.,
Boulder, CO, USA). Nitrate concentrations were calcu-
lated by comparison with standard solutions of sodium
nitrate (Sigma Chemical Co., St Louis, MO, USA).Measurement of plasma IL-1β concentrations
The plasma samples (150 μL) were used to measure the
plasma IL-1β in duplicate with an enzyme-linked immu-
noadsorbent assay kit (R&D Systems, Inc., Minneapolis,
MN, USA) according to the manufacturer’s instructions.Measurement of superoxide production
Superoxide production was measured by lucigenin-
enhanced chemiluminescence as previously described
[23,24]. At the end of study, the animals were exsan-
guinated and sacrificed with overdose pentobarbital
and some tissue specimens were immediately isolated
and removed for analysis. The thoracic aorta was carefully
trimmed of extravascular tissues and then cut into rings
of 5-mm width. The liver, pancreas and spleen tissues
(5 × 5 mm) were cleared of blood and transferred to
scintillation plates. These scintillation plates contain-
ing Krebs-Hepes buffer with 1.25 mM lucigenin (final
volume of 250 μL) were placed into a microplate
luminometer (Hidex Microplate Luminometer, Turku,
Finland). Counts were obtained in duplicate for all tis-
sues, which then were dried for 24 h. The results were
expressed as counts per sec (in each mg of dry tissue).Western blot analysis
After euthanasia, the lung and spleen were obtained and
frozen at -80°C before assay. Frozen samples were thawed
and homogenised on ice for protein assay (Bio-Rad
Laboratories, Hercules, CA, USA), as previously described
[17]. For western blotting, supernatants of tissue homoge-
nates (100 μg total protein) were separated on a 10% (for
inducible nitric oxide synthase (iNOS)) and 15% (for
caspase-3) polyacrylamide gel and transferred on to a
nitrocellulose membrane (Hoeffer, CA, San Francisco,
USA). After blocking for 1.5 h at room temperature
(5% skimmed milk in Tris-buffered saline containing
0.1% Tween 20), the membrane was incubated over-
night (4°C) with polyclonal anti-mouse iNOS antibody
(BD Transduction Laboratories, Lexington, KY, USA) or
polyclonal anti-rabbit cleaved caspase 3 antibody (Cell
Signaling Technology, Danvers, CO, USA) at a 1:1,000
dilution in blocking buffer followed by a horseradish-
peroxidase-coupled secondary antibody (BD Transduc-
tion Laboratory) for 1 h at room temperature at a
1:5,000 dilution for iNOS and 1:3,000 for caspase-3. The
immunoreactive proteins were visualised with the en-
hanced peroxidase/luminol chemiluminescence reaction
kit (Amersham Pharmacia Biotech, Little Chalfont, UK)
followed by exposure to radiographic film. The blots were
then stripped and incubated with anti-β-actin antibody
(diluted 1:3,000; BD Transduction Laboratory) to ensure
equal loading. The ratios of the bands are shown.
Histological assessment
Specimens of lung, liver and spleen were harvested and
immediately fixed in 10% formaldehyde for more than
24 h. The fixed tissues were dehydrated in graded etha-
nol and embedded in paraffin. Each paraffin block was
processed into 4 μm-thick slices that were stained with
hematoxylin and eosin. This histological alteration was
quantitatively analysed as indexes of the severity of poly-
morphonuclear neutrophil (PMN) infiltration and apop-
tosis in three animals from each group. Apoptotic cells
were identified by the characteristic morphology of nu-
clear fragmentation (karyorrhexis) and cell shrinkage with
condensed nuclei (pyknosis) [25]. The indexes were scored
0 (minimal) to 4 (maximal), determined by counting the
numbers of PMN and apoptotic cells in 10 randomly
selected high-power fields evaluated by a pathologist in
a blinded fashion.
Statistical analysis
The data are presented as mean ± standard error of the
mean (SEM) of n determinations, where n represents the
number of animals studied. The significance of differences
in the measured values between groups was analysed using
one-way analysis of variance (ANOVA) or two-way (time
and group) ANOVA for repeated measures, followed by
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neutrophil infiltration and apoptosis were compared by the
Mann-Whitney U-test. The chi-square test was used to
evaluate the effect of treatment on survival rates. A P-value
<0.05 was considered to be statistically significant.
Results
Systemic haemodynamic parameters
The baseline values of the haemodynamic parameters
were comparable in all groups as shown in Table 1.
CLP led to a significantly substantial attenuation in
systolic blood pressure, diastolic blood pressure and
pulse pressure at 18 h (P <0.05, versus the SOP group),
and there was no significant difference between CLP
and CLP + vehicle (Veh) groups. The treatment of CLP
rats with LS significantly prevented severe hypotension
and increased pulse pressure at 18 h (P <0.05, versus
CLP + Veh). In addition, the SOP rats treated with LS had
significantly increased pulse pressure at 18 h compared to
the SOP rats treated with saline.
CLP led to a significant and sustained increase in heart
rate at 3 to 18 h after CLP (P <0.05, versus SOP group;
Table 1), and there was no difference between CLP and
CLP + Veh groups. The treatment of CLP rats with LS
significantly prevented the CLP-induced tachycardia atTable 1 Changes in haemodynamic parameters
Variables Time point SOP (n = 10) SOP
Heart rate, beats/minute 0 h 388 ± 12 367
3 h 413 ± 12 392
9 h 395 ± 10 382
18 h 388 ± 11 404
Systolic pressure, mmHg 0 h 140.3 ± 2.1 141
3 h 146.6 ± 2.6 144
9 h 148.1 ± 2.9 142
18 h 140.4 ± 3.2 146
Diastolic pressure, mmHg 0 h 106.5 ± 2.6 103
3 h 112.5 ± 2.3 108
9 h 112.6 ± 3.5 104
18 h 105.8 ± 3.6 100
Pulse pressure, mmHg 0 h 33.8 ± 0.9 37.5
3 h 34.1 ± 0.9 36.7
9 h 35.5 ± 0.7 38.1
18 h 34.6 ± 0.9 45.7
Pressor response to norepinephrine, % 0 h 100 ± 0 100
3 h 90.8 ± 4.1 94.5
9 h 105 ± 3 96.4
18 h 103 ± 3.2 94.7
Depicted are changes in different groups of SOP (n = 10), SOP + LS (n = 6), CLP (n = 10)
error of the mean. *P <0.05, all groups versus SOP; †P <0.05, CLP + LS versus CLP + Veh
Veh: vehicle (5% dextrose solution).18 h (P <0.05, versus CLP + Veh). The SOP rats treated
with saline or LS exhibited stable haemodynamic condi-
tions during the experimental period and there was no
significant difference among groups.
CLP led to a significantly substantial attenuation in
pressor responses to norepinephrine at 18 h (P <0.05,
versus SOP group; Table 1), and there was no significant
difference between the CLP and the CLP + Veh groups.
However, LS administration significantly prevented the
decrease of pressor responses to norepinephrine in the
CLP group at 18 h. The SOP group treated with saline
or LS exhibited stable haemodynamic conditions during
the experimental period and there was no significant dif-
ference among groups.
Organ injury/dysfunction
Baseline values of plasma markers of biochemical pa-
rameters were not significantly different among groups
(Figure 1). No significant changes in these parameters
were observed during the experimental period in the
SOP group treated with saline or LS, and there was no
significant difference between the CLP and the CLP +
Veh groups.
Significant increases in plasma levels of ALT, AST,
LDH and creatinine at 18 h, and BUN at 9 and 18 h+ LS (n = 6) CLP (n = 10) CLP + Veh (n = 6) CLP + LS (n = 10)
± 13 334 ± 7 350 ± 15 369 ± 8
± 16 444 ± 11* 461 ± 12* 474 ± 12*
± 16 472 ± 11* 488 ± 20* 518 ± 13*
± 20 492 ± 17* 499 ± 14* 478 ± 8*†
.4 ± 3.3 133.7 ± 2.6 147 ± 4.9 139 ± 2.9
.8 ± 1 139.8 ± 2.7 146.8 ± 6.1 141.8 ± 2.6
.7 ± 1.9 124.7 ± 2.6* 130 ± 6.8 133.8 ± 3.4
± 2.3 87.4 ± 5.1* 88 ± 5.1* 126.7 ± 4.1†
.9 ± 3.3 99.8 ± 2.4 111.9 ± 3.9 104.2 ± 2.5
.2 ± 2.2 109.9 ± 2.5 118.4 ± 6.6 112.3 ± 2.7
.6 ± 3 102.7 ± 2.6* 108.3 ± 5.8 96 ± 3.5
.3 ± 4.4 66.7 ± 4* 69.5 ± 3.8* 83.8 ± 4.3*†
± 1.5 33.9 ± 1.1 35.1 ± 2.4 35.3 ± 0.9
± 1.6 30 ± 1.3 28.2 ± 2.3 29.5 ± 0.8
± 2.2 22 ± 1* 21.6 ± 2* 37.9 ± 2.7†
± 2.9* 20.7 ± 1.8* 18.6 ± 2.6* 42.9 ± 1.9*†
± 0 100 ± 0 100 ± 0 100 ± 0
± 4 40.8 ± 5.2* 31.1 ± 3.1* 33.4 ± 3.3*
± 5.4 33.7 ± 3.1* 29.1 ± 2.5* 33.9 ± 2.8*
± 2.6 21.9 ± 1.8* 19.5 ± 1.2* 31.1 ± 1.5*†
, CLP + Veh (n = 6) and CLP + LS (n = 12). Data are expressed as mean ± standard






























































































































Figure 1 Progress of plasma (A) alanine aminotransferase (ALT), (B) aspartate aminotransferase (AST), (C) lactate dehydrogenase (LDH),
(D) blood urea nitrogen (BUN), (E) creatinine, and (F) blood glucose during the experimental period. Depicted are the changes in plasma
biochemical parameters in different groups of sham operation (SOP, n = 10), SOP plus levosimendan administration (SOP + LS, n = 6), cecal
ligation and puncture (CLP, n = 10), CLP plus vehicle treatment (CLP + Veh, n = 6) and CLP plus levosimendan administration (CLP + LS, n = 12).
Data are expressed as mean ± standard error of the mean. *P <0.05, all groups versus SOP. †P <0.05, CLP + LS versus CLP + Veh.
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Figure 1A-C and E). The rises in plasma AST, ALT, LDH,
BUN and creatinine levels at 18 h after CLP were attenuated
by LS (P <0.05 versus CLP +Veh).
The CLP surgery induced a biphasic change in blood
glucose, that is, hyperglycemia at the early stage (3 h)
and hypoglycemia at the late stage (18 h) (P <0.05 versus
SOP group; Figure 1F). However, the treatment of CLP
rats with LS significantly ameliorated the hypoglycemia
at 18 h (P <0.05, versus CLP + Veh), yet the level was
below the baseline and the SOP values.
Blood gas parameters and blood potassium concentration
There was no statistical difference in blood gas parame-
ters in SOP rats, and there was no statistical difference
in blood pH level among groups during the experimental
period (Table 2). However, the rats treated with CLP for
18 h had significant decreases in PaCO2, HCO3
- and base
excess at 9 and 18 h (P <0.05, versus SOP group; Table 2),
indicating respiratory compensation for metabolic acidosis.The compensated metabolic acidosis induced by CLP at
18 h was ameliorated by the treatment with LS (P <0.05,
versus CLP +Veh; Table 2). However, there was no signifi-
cant difference between CLP and CLP +Veh groups.
There was no significant difference in blood potassium
concentration in the SOP rats (Table 2). However, the
rats treated with CLP for 18 h had significant increases
in potassium concentration at 18 h (P <0.05, versus the
SOP group; Table 2), and there was no significant differ-
ence between the CLP and the CLP + Veh groups. The
hyperkalemia induced by CLP at 18 h was ameliorated
by the treatment with LS (P <0.05 versus CLP + Veh;
Table 2).
Plasma nitrite/nitrate levels
The basal plasma level of nitrite/nitrate was not signifi-
cantly different among groups (Figure 2A). The CLP sur-
gery led to a significant increase in plasma nitrite/nitrate
level (P <0.05 versus the SOP group), which reached a
plateau at 9 h, and there was no difference between the
Table 2 Changes in blood gas parameters and potassium concentration
Variables Group SOP SOP + LS CLP CLP + Veh CLP + LS
pH 0 h 7.6 ± 0.01 7.5 ± 0.01 7.6 ± 0.02 7.6 ± 0.01 7.6 ± 0.01
9 h 7.5 ± 0.01 7.5 ± 0.01 7.6 ± 0.01 7.6 ± 0.02 7.6 ± 0.02
18 h 7.6 ± 0.01 7.6 ± 0.01 7.5 ± 0.01 7.5 ± 0.03 7.6 ± 0.01
PaCO2, mmHg 0 h 34 ± 1.7 37 ± 2.3 32 ± 1.7 34 ± 0.4 35 ± 0.7
9 h 36 ± 1 37 ± 1.8 22 ± 0.9* 24 ± 1.4* 24 ± 1.7*
18 h 31 ± 1.2 32 ± 1.4 20 ± 1.3* 21 ± 1.9* 28 ± 1.4†
HCO3
-, mM 0 h 30 ± 0.7 31.1 ± 1.1 27.9 ± 0.9 30 ± 0.7 29.9 ± 0.6
9 h 29.4 ± 0.6 29.4 ± 1.1 20.8 ± 0.8* 22.1 ± 1.1* 23.2 ± 0.8*
18 h 27.6 ± 0.7 28.5 ± 1.4 16.7 ± 1* 15.4 ± 1.2* 24.5 ± 1†
Base excess, mM 0 h 7.8 ± 0.5 8.4 ± 0.7 7.3 ± 0.2 7.9 ± 0.8 7.5 ± 0.5
9 h 6.7 ± 0.5 6.7 ± 0.7 1.2 ± 0.7* 2.2 ± 1.1* 3.6 ± 0.5*
18 h 5.4 ± 0.5 6.7 ± 1.1 -3.2 ± 0.8* -5.5 ± 1.3* 3.2 ± 0.9*†
Potassium, mM 0 h 3.7 ± 0.1 3.9 ± 0.1 3.8 ± 0.1 3.8 ± 0.1 3.9 ± 0.1
9 h 3.6 ± 0.1 4 ± 0.1 3.9 ± 0.1 3.9 ± 0.2 3.9 ± 0.1
18 h 3.6 ± 0.1 3.7 ± 0.2 4.9 ± 0.2* 5.2 ± 0.4* 3.8 ± 0.1†
Depicted are the changes in different groups of SOP (n = 10), SOP + LS (n = 6), CLP (n = 10), CLP + Veh (n = 6) and CLP + LS (n = 12). Data are expressed as
mean ± standard error of the mean. *P <0.05 all groups versus SOP; †P <0.05, CLP + LS versus CLP + Veh. CLP: cecal ligation and puncture; LS: Levosimendan;
SOP: sham of operation; Veh: vehicle (5% dextrose solution).
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rats with LS significantly inhibited the CLP-induced in-
crease in plasma nitrite/nitrate level at 9 and 18 h (P <0.05
versus CLP + Veh). In the SOP group, no significant in-
crease in plasma nitrite/nitrate levels was detectable dur-
ing the experimental period. The treatment of SOP rats
with LS alone had no significant effect on plasma level of
nitrite/nitrate.
Plasma IL-1β Levels
The basal plasma level of IL-1β was not significantly dif-
ferent between any of the experimental groups studied
(Figure 2B). The CLP surgery led to significant increases in
plasma IL-1β levels, and reached a peak at 18 h (P <0.05
versus the SOP group), and there was no significant differ-
ence between the CLP and the CLP +Veh groups. The
treatment of CLP rats with LS significantly inhibited the
CLP-induced increases in plasma IL-1β levels at 18 h
(P <0.05 versus CLP + Veh). In the SOP group, no sig-
nificant increases in plasma IL-1β levels were detect-
able during the experimental period. The treatment of
SOP rats with LS alone, however, had no significant ef-
fect on plasma level of IL-1β.
Organ superoxide levels
The basal production of superoxide was detectable in
aorta, liver, spleen and pancreas in SOP rats at the end
of the experiment (Figure 3). A significant increase in the
superoxide levels of these organs was observed in CLP
rats (P <0.05 versus the SOP group), and there was nosignificant difference between the CLP and the CLP + Veh
groups. However, the treatment of CLP rats with LS sig-
nificantly inhibited the production of superoxide (P <0.05
versus CLP + Veh), whereas LS itself had no significant ef-
fect on the change of superoxide level in SOP rats.
iNOS protein and caspase-3 expression
The protein expression of iNOS protein was undetect-
able in lung homogenates obtained from both SOP rats
(Figure 4A). A significant induction of iNOS protein was
observed in lung homogenates from the CLP rats (P <0.05
versus the SOP group), and there was no significant differ-
ence between CLP and CLP + Veh groups. The treatment
of CLP rats with LS significantly reduced the expression
of iNOS protein in the lung (P <0.05 versus CLP +Veh).
The protein expression of cleaved caspase-3 protein
was undetectable in spleen homogenates obtained from
both SOP rats (Figure 4B). A significant induction of
cleaved caspase-3 protein was observed in spleen ho-
mogenates from the CLP rats (P <0.01 versus the SOP
group), and there was no significant difference between
the CLP and the CLP + Veh groups. The treatment of
CLP rats with LS significantly reduced the expression of
cleaved caspase-3 protein in the spleen (P <0.05 versus
CLP + Veh).
Histological studies
At the end of the study, stained specimens from CLP
rats revealed 1) increased interstitial edema and de-














































Figure 3 Superoxide levels of aorta, liver, spleen and pancreas
at 18 h after surgery. Depicted are the changes in different groups
of sham operation (SOP, n = 10), SOP plus Levosimendan administration
(SOP+ LS, n = 6), cecal ligation and puncture (CLP, n = 10), CLP plus
vehicle treatment (CLP + Veh, n = 6) and CLP plus Levosimendan
administration (CLP+ LS, n = 12). Data are expressed as mean ± standard
error of the mean. *P <0.05, all groups versus SOP, †P <0.05, CLP + LS
versus CLP + Veh.


































































Figure 2 Progress of plasma (A) nitric oxide (NO) and (B)
interleukin-1β (IL-1β) levels during the experimental period.
Depicted are the changes of plasma NO and IL-1β levels in different
groups of sham operation (SOP, n = 10), SOP plus Levosimendan
administration (SOP + LS, n = 6), cecal ligation and puncture (CLP,
n = 10), CLP plus vehicle treatment (CLP + Veh, n = 6) and CLP plus
Levosimendan administration (CLP + LS, n = 12). Data are
expressed as mean ± standard error of the mean. *P <0.05, all groups
versus SOP; †P <0.05, CLP + LS versus CLP + Veh.
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pared to those from the SOP group (Figure 5). However,
the histopathological changes in these organs were im-
proved after LS treatment. Light microscopy only showed
a little infiltration or sequestration of PMNs in lung and
liver from the SOP group, whereas overt infiltration of
PMNs in these tissues was observed in CLP rats (.0 ± 0.6
in lung and 2.0 ± 0.6 in liver; P <0.05). There was no sig-
nificant difference between the CLP and the CLP + Veh
groups. However, in CLP rats treated with LS, the PMN
infiltrations were significantly reduced (1.7 ± 0.3 in lung,
and 0.0 in liver; P <0.05 versus CLP). In addition, light mi-
croscopy showed no apoptosis in the spleen from SOP
rats (Figure 6), whereas severe apoptosis were found in
this organ from CLP rats (3.7 ± 0.3 in spleen; P <0.05).
However, the apoptosis index was significantly reduced in
CLP rats treated with LS (2 ± 0; P <0.05 versus CLP).Survival rate
No mortality was observed within 18 h in the SOP rats
(survival rate = 100%). The 9-h and 18-h survival rates of
CLP animals were 64% (that is, 16/25 animals) and 40%
(that is, 10/25 animals), respectively (Table 3), while the
9-h and 18-h survival rates of CLP + Veh animals were
64.7 (that is, 11/17 animals) and 41.1% (that is, 7/17 ani-
mals), respectively. There was no significant difference
in survival rate between CLP and CLP + Veh groups. In
contrast, the rats treated with LS had higher survival
rates of 71.4% (that is, 15/21 animals) at 9 h and 61.9%
(that is, 13/21 animals) at 18 h after CLP. Thus, LS sig-
nificantly increased the 18-h survival rate of CLP rats
(P <0.05 versus CLP + Veh). Because of clots or kink-
ing of the arterial catheter, blood and data could not
be collected in some of rats in each group that sur-
vived the full 18 h of the experiment.
Discussion
The major findings are that an intravenous infusion of
LS: 1) increased arterial blood pressure and pressor re-
sponse to the NE, 2) reduced plasma levels of biochem-
ical parameters, 3) attenuated metabolic acidosis, and 4)
prevented histopathological changes in CLP-treated rats.
This study demonstrated that the LS application im-
proved survival in sepsis as a consequence of reducing
multiple organ injury. In addition, LS acted by inhibiting
plasma IL-1β and NO production, attenuating super-
oxide formation, and suppressing iNOS and cleaved
caspase-3 expression.
Clinically, LS is dissolved in a glucose 5% solution and ad-




































































































Figure 4 Expressions of (A) lung inducible nitric oxide (NO)
synthase (iNOS) and (B) spleen-cleaved caspase 3. Depicted are
the expressions of lung iNOS and spleen-cleaved caspase 3 at the
end of the study in different groups of sham operation (SOP, n = 3),
SOP plus Levosimendan administration (SOP + LS, n = 3), cecal
ligation and puncture (CLP, n = 5), CLP plus vehicle treatment (CLP + Veh,
n = 5) and CLP plus Levosimendan administration (CLP + LS, n = 5). Data
are expressed as mean± standard error of the mean. *P <0.05, all groups
versus SOP, †P <0.05, CLP+ LS versus CLP + Veh.
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that 6-h infusion of LS administered 3 h later after CLP pro-
cedure had the capability of improving survival at the end of
the 18-h experiment, while the infusion of vehicle (that is,
5% dextrose in this study) did not change the survival of
CLP-treated rats. Furthermore, Scheiermann et al. found
that a single dose of intravenous LS could prolong survival
for more than 3 h after the onset of sepsis [16]. The elimin-
ation half-life of LS is approximately 1 h, however, the active
LS metabolite OR-1896 has a longer half-life of 75 to 80 h
[26]. Thus, OR-1896 may also potentially account for the
protective effects of LS in our study.
The animal model of CLP developed hypotension and
tachycardia as typically seen in human septic shock [27,28].
In the present study, the infusion of LS increased pulsepressure in sham- and CLP-treated rats, suggesting this is
due to its positive inotropic effects. Vasodilation induced
by activation of the KATP channel is another major prop-
erty of LS. However, the LS dosage used in our study did
significantly raise diastolic blood pressure but did not ag-
gravate hypotension induced by CLP. Thus, this may be
due to a positive inotropic effect outweighing the vasodilat-
ing component of LS. The administration of CLP rats with
LS also attenuated sepsis-induced hypo-reactivity to NE
possibly, due to its increasing effect on calcium sensitisa-
tion. It has been shown that sepsis-induced hypo-reactivity
to norepinephrine is associated with NO-derived peroxyni-
trite [29-31]. Therefore, LS-decreased plasma NO levels in
sepsis may also contribute to the improvement of vascular
dysfunction.
There is increasing evidence that the apoptotic mode of
cell death in critically ill patients plays a pivotal role in the
pathogenesis of the sepsis syndrome [32,33]. Apoptotic
cell death can be induced by caspase-3 through the extrin-
sic death-receptor and intrinsic mitochondria pathway,
which can be activated by diverse stimuli, including pro-
inflammatory cytokines, reactive oxygen species and NO
[34,35]. Together with increased amounts of NO that are
produced by the iNOS, superoxide forms the highly react-
ive peroxynitrite that causes irreversible damage to pro-
teins, causing mitochondrial dysfunction and organ failure
[32]. Our present study demonstrated that IL-1β, NO and
superoxide production and iNOS expression were in-
creased in CLP-induced septic rats, which were attenuated
by LS administration. Furthermore, decreased apoptosis,
as determined by the cleaved caspase-3 protein expres-
sion, was observed in the spleen of the CLP + LS group
compared to the CLP +Veh group, indicating LS has an
anti-apoptosis effect in the spleen [36].
Furthermore, LS administration decreased the inflam-
matory infiltration by neutrophils in vital organs such as
liver and lung. Such neutrophil infiltration can lead to
vascular dysfunction as well as parenchymal cell injury
[37]. This indicates that LS could prevent organ injury
in sepsis by its antioxidant and anti-inflammatory prop-
erties. Torraco et al. also reveal that LS protects mito-
chondria from the oxidative stress in patients suffering
with septic shock [38]. These results suggest that benefi-
cial effects of LS administration on biomarkers of oxida-
tive stress, inflammation, tissue injury, and apoptosis
were further strengthened by the favorable outcome in
the study group, that is, LS-treated CLP animals had
about 22% survival benefit over CLP controls.
On the other hand, splanchnic hypoperfusion and sub-
sequent mucosal ischaemia result in increased inflamma-
tion, gut permeability and bacterial translocation, further
exacerbating multiple organ dysfunction induced by sepsis
[39]. In addition, hepatic and renal dysfunction may lead





Figure 5 Histopathological studies of lung and liver. Light microscopy showed lung and liver sections of rats in groups of (A) sham operation,
(B) cecal ligation and puncture (CLP), and (C) CLP plus Levosimendan administration. Sections were stained with haematoxylin and eosin. Arrows
represent polymorphonuclear neutrophil infiltration in lung and liver. Each is shown at 400 × (original magnification).
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cently been attributed to tissue oxygenation in sepsis, and
it has been suggested that vasodilators could be used
therapeutically to increase the microcirculation and im-
prove tissue oxygenation [40,41]. Earlier studies demon-
strate that LS increases sublingual oxygenation and
splanchnic perfusion during clinical septic shock [10,42].
In addition, LS increases portal blood flow, intestinal muco-
sal oxygenation and vascular reactivity in a porcine model
of sepsis, whereas AST is not significantly attenuated [12].
However, biochemical parameters of liver and renal injury
and metabolic acidosis were attenuated after LS treatment
in our present study. Furthermore, light microscopy
showed that the histopathological changes in these tis-
sues were also improved. It is assumed to be associated
with opening of the mitochondria KATP channel, increasingperfusion of peripheral tissues and decreasing organ
injury [43,44].
The current study has some limitations that need to be
addressed. First, it was conducted in previously healthy
animals under highly controlled circumstances, in contrast
to the clinical setting in which patients often have under-
lying illness and co-morbidities. Second, we did not use
antibiotics in order to avoid any influence of LS on the
organ function in this study. Moreover, only one single
intravenous dose of continuous LS infusion was used, and
consequently, we cannot exclude the possibility that a lar-
ger dose could yield better histological results. Finally, it
has been shown that the administration of drugs just after
endotoxin administration and CLP procedure does not
represent medical practice. In the current study, LS was
given at 3 h after CLP, when sepsis seems to be developing
AB
C
Figure 6 Histopathological studies of spleen. Light microscopy
showed spleen sections of rats in groups of (A) sham operation,
(B) cecal ligation and puncture, and (C) CLP plus Levosimendan
administration. Sections were stained with haematoxylin and
eosin. Arrows represent apoptosis in the spleen. Each is shown at
400 × (original magnification).
Table 3 Efffects of Levosimendan (LS) on the survival rate
in septic rats duing the pexperimental period
Groups Survival rats (%)
9 h 18 h
SOP 100 100
SOP + LS 100 100
CLP 64* 40*
CLP + Veh 64.7* 41*
CLP + LS 71.4*† 61.9*†
Rats underwent sham operation (SOP, n = 10), SOP and Levosimendan
administration (SOP + LS, n = 6), cecal ligation and puncture (CLP, n = 25), CLP
and vehicle treatment (CLP + Veh, n = 17) or CLP and Levosimendan
administration (CLP + LS, n = 21). *P <0.05, CLP versus SOP; †P <0.05, CLP + LS
versus CLP + Veh.
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period of time after CLP might have different results.
Therefore, these results cannot be directly directed to clin-
ical use unless similar interventions have been taken in
this sepsis model.Conclusions
The present findings support the hypothesis that LS im-
proved survival, minimized histological changes and pre-
vented sepsis-induced multiple organ dysfunction by its
anti-inflammatory and anti-apoptosis properties, which
involve the inhibition of IL-1β and superoxide produc-
tion as well as the reduction of iNOS and caspase-3 ex-
pression to the affected tissues. Thus, our present study
suggests that a single early dose of LS could be a highly
promising agent for protecting tissues from oxidative
stress and preventing organ dysfunction due to sepsis,
but this hypothesis needs to be proved in further clinical
studies.Key messages
 Multiple organ dysfunction occurs in rats with
peritonitis-induced sepsis
 Levosimendan is protective in the treatment of
peritonitis-induced sepsis with respect to survival
 Levosimendan improves haemodynamic variables,
reduces organ injury, and attenuates metabolic
acidosis in septic rats
 Levosimendan may have anti-inflammatory and
anti-apoptosis properties, which involve the inhibition
of IL-1β and superoxide production as well as the
reduction of iNOS and caspase-3 expression to the
affected tissues
Abbreviations
ALT: alanine aminotransferase; ANOVA: analysis of variance; AST: aspartate
aminotransferase; BUN: blood urea nitrogen; CLP: cecal ligation and
puncture; IL-1β: interleukin-1β; iNOS: inducible nitric oxide synthase;
Tsao et al. Critical Care 2014, 18:652 Page 11 of 12
http://ccforum.com/content/18/6/652LDH: lactate dehydrogenase; LS: Levosimendan; NO: nitric oxide;
PMN: polymorphonuclear neutrophil; SOP: sham of operation; Veh: vehicle.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CMT planned the research, coordinated the study and drafted the
manuscript. KYL performed most of the experiments and analyzed the
respective data. SJC participated in the design of the study, performed the
statistical analysis and helped to revise the manuscript. SMK carried out the
histological experiment and analysis and assisted in manuscript preparation.
WJL participated in the sequence alignment and drafted the manuscript.
HCH provided analytic tools, participated in the coordination of the study
and critically revised the manuscript. CCW designed and supervised the
research and drafted the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
This work was supported by grants from the National Science Council,
Taiwan, ROC (NSC 97-2320-B-016-006-MY3, 98-2314-B-075-005-MY3 and
100-2320-B-016-008), Taipei Veterans General Hospital, Taiwan, ROC (VGH-V120C-
143), and Cheng Hsin General Hospital, Taiwan, ROC (CHGH 100-49).
Author details
1Department of Anesthesiology, Taipei Veterans General Hospital and
National Yang-Ming University, Taipei, Taiwan. 2Department of
Anesthesiology, Tri-Service General Hospital, National Defence Medical
Centre, Taipei, Taiwan. 3Department of Pharmacology, National Defence
Medical Centre, Neihu PO Box 90048-504, Taipei 114, Taiwan. 4Department of
Nursing, Kang-Ning Junior College of Medical Care and Management, Taipei,
Taiwan. 5Department of Physiology, National Defence Medical Centre, Taipei,
Taiwan. 6Graduate Institute of Aerospace and Undersea Medicine, National
Defence Medical Centre, Taipei, Taiwan. 7Department of Anesthesiology,
Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan. 8Department of
Anesthesiology, Cheng-Hsin General Hospital, Taipei, Taiwan. 9Department of
Pharmacology, Taipei Medical University, Taipei, Taiwan. 10Department of
Anesthesiology and Pain Clinics, Cheng-Hsin Rehabilitation Medical Centre,
45, Cheng-Hsin St, Taipei 112, Taiwan.
Received: 23 May 2014 Accepted: 7 November 2014
References
1. Ani C, Farshidpanah S, Bellinghausen Stewart A, Nguyen HB: Variations in
Organism-Specific Severe Sepsis Mortality in the United States: 1999-2008.
Crit Care Med 2014, in press.
2. ProCESS Investigators, Yealy DM, Kellum JA, Huang DT, Barnato AE,
Weissfeld LA, Pike F, Terndrup T, Wang HE, Hou PC, LoVecchio F, Filbin MR,
Shapiro NI, Angus DC: A randomized trial of protocol-based care for early
septic shock. N Engl J Med 2014, 370:1683–1693.
3. Zhou J, Qian C, Zhao M, Yu X, Kang Y, Ma X, Ai Y, Xu Y, Liu D, An Y, Wu D,
Sun R, Li S, Hu Z, Cao X, Zhou F, Jiang L, Lin J, Mao E, Qin T, He Z, Zhou L,
Du B, China Critical Care Clinical Trials Group (CCCCTG): Epidemiology and
outcome of severe sepsis and septic shock in intensive care units in
mainland china. PLoS One 2014, 9:e107181.
4. Spronk PE, Zandstra DF, Ince C: Bench-to-bedside review: sepsis is a
disease of the microcirculation. Crit Care 2004, 8:462–468.
5. Trzeciak S, Cinel I, Phillip Dellinger R, Shapiro NI, Arnold RC, Parrillo JE,
Hollenberg SM, Microcirculatory Alterations in Resuscitation and Shock
(MARS) Investigators: Resuscitating the microcirculation in sepsis: the
central role of nitric oxide, emerging concepts for novel therapies, and
challenges for clinical trials. Acad Emerg Med 2008, 15:399–413.
6. Tsao CM, Chen SJ, Shih MC, Lue WM, Tsou MY, Chen A, Liaw WJ, Wu CC:
Effects of terbutaline on circulatory failure and organ dysfunction
induced by peritonitis in rats. Intensive Care Med 2010, 36:1571–1578.
7. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Lindén IB: Cardiac
troponin C as a target protein for a novel calcium sensitizing drug,
levosimendan. J Mol Cell Cardiol 1995, 27:1859–1866.8. Kivikko M, Lehtonen L: Levosimendan: a new inodilatory drug for the
treatment of decompendated heart failure. Curr Pharm Des 2005,
11:435–455.
9. Nieminen MS, Fruhwald S, Heunks LM, Suominen PK, Gordon AC, Kivikko M,
Pollesello P: Levosimendan: current data, clinical use and future
development. Heart Lung Vessel 2013, 5:227–245.
10. Morelli A, Donati A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V,
Landoni G, Pelaia P, Pietropaoli P, Van Aken H, Teboul JL, Ince C, Westphal M:
Levosimendan for resuscitating the microcirculation in patients with septic
shocl: a randomized controlled study. Crit Care 2010, 14:R232.
11. Fries M, Ince C, Rossanit R, Bleilevens C, Bickenbach J, Rex S, Mik EG:
Levosimendan but not norepinephrine improves microvascular
oxygenation during experimental septic shock. Crit Care Med 2008,
36:1886–1891.
12. García-Septien J, Lorente JA, Delgado MA, de Paula M, Nin N, Moscoso A,
Sánchez-Ferrer A, Perez-Vizcaino F, Esteban A: Levosimendan increases
portal blood flow and attenuates intestinal intramucosal acidosis in
experimental septic shock. Shock 2010, 34:275–280.
13. Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S,
Iliodromitis E, Kremastinos D: Effects of levosimendan on circulating
pro-inflammatory cytokines and soluble apoptosis mediators in patients
with decompensated advanced heart failure. Am J Cardiol 2004,
93:1309–1312.
14. Boost KA, Hoegl S, Dolfen A, Czerwonka H, Scheiermann P, Zwissler B,
Hofstetter C: Inhaled levosimendan reduces mortality and release of
proinflammatory mediators in a rat model of experimental ventilator-
induced lung injury. Crit Care Med 2008, 36:1873–1879.
15. Zager RA, Johnson AC, Lund S, Hanson SY, Abrass CK: Levosimendan
protects against experimental endotoxemic acute renal failure. Am J
Physiol Renal Physiol 2006, 290:F1453–F1462.
16. Scheiermann P, Ahluwalia D, Hoegl S, Dolfen A, Revermann M, Zwissler B,
Muhl H, Boost KA, Hofstetter C: Effects of intravenous and inhaled
levosimendan in severe rodent sepsis. Intensive Care Med 2009,
35:1412–1419.
17. Shih CC, Chen SJ, Chen A, Wu JY, Liaw WJ, Wu CC: Therapeutic effects of
hypertonic saline on peritonitis-induced septic shock with multiple
organ dysfunction syndrome in rats. Crit Care Med 2008, 36:1864–1872.
18. Yu Z, McNeill JH: Blood pressure and heart rate response to vasoactive
agents in conscious diabetic rats. Can J Physiol Pharmacol 1992,
70:1542–1548.
19. Wu JY, Tsou MY, Chen TH, Chen SJ, Tsao CM, Wu CC: Therapeutic effects
of melatonin on peritonitis-induced septic shock with multiple organ
dysfunction syndrome in rats. J Pineal Res 2008, 45:106–116.
20. Liao MH, Shih CC, Tsao CM, Chen SJ, Wu CC: RhoA/Rho-kinase and nitric
oxide in vascular reactivity in rats with endotoxaemia. PLoS One 2013,
8:e56331.
21. Braman RS, Hendrix SA: Nanogram nitrite and nitrate determination in
environmental and biological materials by vanadium (III) reduction with
chemiluminescence detection. Anal Chem 1989, 61:2715–2718.
22. Tsao CM, Ho ST, Chen A, Wang JJ, Li CY, Tsai SK, Wu CC: Low-dose
dexamethasone ameliorates circulatory failure and renal dysfunction in
conscious rats with endotoxemia. Shock 2004, 21:484–491.
23. Yu HP, Lui PW, Hwang TL, Yen CH, Lau YT: Propofol improves endothelial
dysfunction and attenuates vascular superoxide production in septic
rats. Crit Care Med 2006, 34:453–460.
24. Tsao CM, Ho ST, Liaw WJ, Chen A, Wu CC: Combined effects of propofol and
dexamethasone on rats with endotoxemia. Crit Care Med 2008, 36:887–894.
25. Javadi P, Buchman TG, Stromberg PE, Husain KD, Dunne WM, Woolsey CA,
Turnbull IR, Hotchkiss RS, Karl IE, Coopersmith CM: High-dose exogenous
iron following cecal ligation and puncture increases mortality rate in
mice and is associated with an increase in gut epithelial and splenic
apoptosis. Crit Care Med 2004, 32:1178–1185.
26. Gheorghiade M, Teerlink JR, Mebazaa A: Pharmacology of new agents for
acute heart failure syndromes. Am J Cardiol 2005, 96:68G–73G.
27. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW 3rd, Bland KI,
Chaudry IH: Cecal ligation and puncture. Shock 2005, 24:52–57.
28. Wen H: Sepsis induced by cecal ligation and puncture. Methods Mol Biol
2013, 1031:117–124.
29. Zingarelli B, Day BJ, Crapo JD, Salzman AL, Szabó C: The potential role of
peroxynitrite in the vascular contractile and cellular energetic failure in
endotoxic shock. Br J Pharmacol 1997, 120:259–267.
Tsao et al. Critical Care 2014, 18:652 Page 12 of 12
http://ccforum.com/content/18/6/65230. Takakura K, Taniguchi T, Muramatsu I, Takeuchi K, Fukuda S: Modification of
alpha1-adrenoceptors by peroxynitrite as a possible mechanism of systemic
hypotension in sepsis. Crit Care Med 2002, 30:894–899.
31. Kimmoun A, Ducrocq N, Levy B:Mechanisms of vascular hyporesponsiveness
in septic shock. Curr Vasc Pharmacol 2013, 11:139–149.
32. Alvarez S, Evelson PA: Nitric oxide and oxygen metabolism in
inflammatory conditions: sepsis and exposition to polluted ambients.
Front Biosci 2007, 12:964–974.
33. Hotchkiss RS, Nicholson DW: Apoptosis and caspases regulate death and
inflammation in sepsis. Nat Rev Immunol 2006, 6:813–822.
34. Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A: The apoptotic pathway
as a therapeutic target in sepsis. Curr Drug Targets 2007, 8:493–500.
35. Boatright KM, Salvesen GS: Mechanisms of caspase activation. Curr Opin
Cell Biol 2003, 15:725–731.
36. Plaschke K, Bent F, Wagner S, Zorn M, Kopitz J: In contrast to its anti-
inflammatory and anti-apoptotic peripheral effect, levosimendan failed
to induce a long-term neuroprotective effect in a rat model of mild
septic encephalopathy: a pilot study. Neurosci Lett 2014, 560:117–121.
37. Jaeschke H, Hasegawa T: Role of neutrophils in acute inflammatory liver
injury. Liver Int 2006, 26:912–919.
38. Torraco A, Carrozzo R, Piemonte F, Pastore A, Tozzi G, Verrigni D, Assenza M,
Orecchioni A, D'Egidio A, Marraffa E, Landoni G, Bertini E, Morelli A: Effects of
levosimendan on mitochondrial function in patients with septic shock:
A randomized trial. Biochimie 2014, 102:166–173.
39. Mythen MG, Webb AR: Intra-operative gut mucosal hypoperfusion is
associated with increased postoperative complications and cost.
Intensive Care Med 1994, 20:99–104.
40. Pagel PS, Hettrick DA, Warltier DC: Influence of levosimendan,
pimobendan, and milrinone on the regional distribution of cardiac
output in anaesthetized dogs. Br J Pharmacol 1996, 119:609–615.
41. Schwarte LA, Picker O, Bornstein SR, Fournell A, Scheeren TW:
Levosimendan is superior to milrinone and dobutamine in selectively
increasing microvascular gastric mucosal oxygenation in dogs. Crit Care
Med 2005, 33:135–142.
42. Memiş D, Inal MT, Sut N: The effects of levosimendan vs dobutamine
added to dopamine on liver functions assessed with noninvasive liver
function monitoring in patients with septic shock. J Crit Care 2012,
27:318. e1–6.
43. Kopustinskiene DM, Pollesello P, Saris NE: Potassium-specific effects of
levosimendan on heart mitochondria. Biochem Pharmacol 2004, 68:807–812.
44. Szilagyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, Papp Z:
The effects of levosimendan and OR-1896 on isolated hearts,
myocyte-sized preparations and phosphodiesterase enzymes of the
guinea pig. Eur J Pharmacol 2004, 486:67–74.
doi:10.1186/s13054-014-0652-4
Cite this article as: Tsao et al.: Levosimendan attenuates multiple organ
injury and improves survival in peritonitis-induced septic shock: studies in
a rat model. Critical Care 2014 18:652.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
